Famotid syrup

Famotidine USP

Composition : Each 5 ml reconstituted suspension contains Famotidine USP 40 mg.

Indication : Famotidine is indicated in Duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, acute stress ulcer and Zollinger-Ellison syndrome. It is also indicated in acute gastritis, chronic gastritis in acute exacerbation stage.

Dosage and administration:

Gastroesophageal reflux disease (GERD):

‹1 year of age: 0.5 mg/kg/dose of famotidine oral suspension up to 8weeks once daily in patients.

Age 3 to 11 months : 0.5 mg/kg/dose twice daily up to 8weeks

Age 1 to 2 months : 0.5 mg/kg/dose once daily up to 8weeks

Neonates : 0.5 mg/kg/dose maximum once daily up to 8weeks

Patients 1-16 years of age:

Gastroesophageal Reflux Disease (GERD): 1 mg/kg/day p.o. divided b.i.d. up to 40 mg b.i.d.

Duodenal Ulcer: 0.5 mg/kg/day p.o. at bed time or divided b.i.d. up to 40 mg/day.

Peptic ulcer: 0.5 mg/kg/day p.o. at bed time or divided b.i.d. up to 40 mg/day.

Maintenance Therapy: 40 mg at daily night.

Reflux esophagitis: 2 mg/kg/day.

Zollinger-Ellison syndrome: 40 mg 3 times daily.

Or, as directed by a registered physician.

Use in pregnancy and lactation : Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Caution should be exercised when famotidine is administered to a nursing woman.

Packing: Famotid Suspension: Each bottle contains dry powder for preparation of 50 ml suspension.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.